CLINICAL TRIALS PROFILE FOR GLIMEPIRIDE

505(b)(2) Clinical Trials for Glimepiride

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT00151697 ↗	LANN-study: Lantus, Amaryl, Novorapid, Novomix Study	Completed	Rijnstate Hospital	Phase 3	2005-05-01	Many diabetics gain weight while on insulin therapy. In this study, we evaluate the efficacy of the combination of glimepiride and short-acting insulin on weight control and glucose control. In this study, 150 diabetics whose diabetic control is inadequate while on maximal oral treatment will be randomized to either the new combination treatment or twice daily injections with a mixture of short- and longacting insulin or once-daily injection with a basal insulin analog. The study will compare glucose control and weight gain during a year after randomisation between the three treatments.

All Clinical Trials for Glimepiride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00032487 ↗	Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)	Completed	National Eye Institute (NEI)	Phase 3	2000-12-01	This study is a prospective, 2-arm, randomized controlled trial to determine whether glycemic control, achieved through intensification of treatment, is effective in preventing clinical macrovascular complications in patients with type 2 DM who are no longer responsive to oral agents alone. The study consists of a two-year accrual period and five years of follow-up (7 years total) of 1700 patients across 20 centers. We have powered the study to detect a 21% reduction in the primary event rate. Additional study goals are to determine whether the expenditures, discomfort, and adverse effects associated with intensive intervention are justified in terms of their clinical benefits, considering both macrovascular and microvascular complications.
NCT00032487 ↗	Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)	Completed	SmithKline Beecham	Phase 3	2000-12-01	This study is a prospective, 2-arm, randomized controlled trial to determine whether glycemic control, achieved through intensification of treatment, is effective in preventing clinical macrovascular complications in patients with type 2 DM who are no longer responsive to oral agents alone. The study consists of a two-year accrual period and five years of follow-up (7 years total) of 1700 patients across 20 centers. We have powered the study to detect a 21% reduction in the primary event rate. Additional study goals are to determine whether the expenditures, discomfort, and adverse effects associated with intensive intervention are justified in terms of their clinical benefits, considering both macrovascular and microvascular complications.
NCT00032487 ↗	Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)	Completed	VA Office of Research and Development	Phase 3	2000-12-01	This study is a prospective, 2-arm, randomized controlled trial to determine whether glycemic control, achieved through intensification of treatment, is effective in preventing clinical macrovascular complications in patients with type 2 DM who are no longer responsive to oral agents alone. The study consists of a two-year accrual period and five years of follow-up (7 years total) of 1700 patients across 20 centers. We have powered the study to detect a 21% reduction in the primary event rate. Additional study goals are to determine whether the expenditures, discomfort, and adverse effects associated with intensive intervention are justified in terms of their clinical benefits, considering both macrovascular and microvascular complications.
NCT00044447 ↗	Evaluate the Role of Adding Amaryl to Non-Insulin Dependent Diabetes Mellitus Patients Unresponsive to Maximum Dose Metformin & Thiazolidinedione	Completed	Sanofi	Phase 3	2001-05-01	The purpose of this study is to assess the efficacy and safety of Amaryl when added to Metformin and Thiazolidinedione (TZD) in non-insulin dependent diabetes mellitus (NIDDM) patients.
NCT00095030 ↗	Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone	Completed	Merck Sharp & Dohme Corp.	Phase 3	2004-02-01	The purpose of this clinical research study is to learn whether a muraglitazar-metformin combination is at least as effective as a glimepiride-metformin combination to treat type 2 diabetics who are not sufficiently controlled with metformin alone. The safety of this treatment will also be studied.
NCT00095030 ↗	Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone	Completed	Bristol-Myers Squibb	Phase 3	2004-02-01	The purpose of this clinical research study is to learn whether a muraglitazar-metformin combination is at least as effective as a glimepiride-metformin combination to treat type 2 diabetics who are not sufficiently controlled with metformin alone. The safety of this treatment will also be studied.
NCT00099944 ↗	Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes	Completed	Novartis Pharmaceuticals	Phase 3	2004-05-01	Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. The purpose of this study is to assess the safety and effectiveness of two doses of vildagliptin, an unapproved drug, in lowering overall blood glucose levels when added to glimepiride in people with type 2 diabetes not at target blood glucose levels on a sulfonylurea alone.

Clinical Trial Conditions for Glimepiride

Condition Name

Condition Name for Glimepiride
Intervention	Trials
Diabetes Mellitus, Type 2	72
Type 2 Diabetes Mellitus	71
Type 2 Diabetes	26
Diabetes	18

Condition MeSH

Condition MeSH for Glimepiride
Intervention	Trials
Diabetes Mellitus, Type 2	189
Diabetes Mellitus	180
Hypoglycemia	4
Glucose Intolerance	3

Clinical Trial Locations for Glimepiride

Trials by Country

Trials by Country for Glimepiride
Location	Trials
United States	725
Germany	78
Canada	77
India	62
United Kingdom	61

Trials by US State

Trials by US State for Glimepiride
Location	Trials
Texas	38
California	33
Florida	32
Ohio	25
South Carolina	24

Clinical Trial Progress for Glimepiride

Clinical Trial Phase

Clinical Trial Phase for Glimepiride
Clinical Trial Phase	Trials
PHASE4	3
PHASE3	1
PHASE2	1

Clinical Trial Status

Clinical Trial Status for Glimepiride
Clinical Trial Phase	Trials
Completed	177
Terminated	22
Unknown status	17

Clinical Trial Sponsors for Glimepiride

Sponsor Name

Sponsor Name for Glimepiride
Sponsor	Trials
Merck Sharp & Dohme Corp.	31
Sanofi	21
Novo Nordisk A/S	17

Sponsor Type

Sponsor Type for Glimepiride
Sponsor	Trials
Industry	223
Other	139
NIH	4

Glimepiride Market Analysis and Financial Projection

Last updated: April 27, 2026

GLIMEPIRIDE Clinical Trials Update, Market Analysis, and Projection

What is glimepiride and where is it positioned commercially?

Glimepiride is an oral second-generation sulfonylurea used for type 2 diabetes mellitus (T2DM). It is widely marketed as a long-standing generic and (depending on region) is commonly available as branded legacy products. Its commercial profile is defined by three factors: (1) cheap generic pricing, (2) strong label positions in add-on and monotherapy use in standard-of-care algorithms, and (3) competition from newer classes (DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors).

Because glimepiride is mature and off-patent in major jurisdictions, the market outcome is driven less by new patentable product launches and more by T2DM incidence, guideline adherence, payer formularies, and the share shift between oral agents versus injectables.

---

What clinical-trial activity is currently relevant for glimepiride?

Glimepiride’s modern trial landscape is dominated by:

• Comparative efficacy/safety studies against other glucose-lowering drugs
• Combination regimens (e.g., add-on strategies with metformin or insulin in real-world and pragmatic trial designs)
• Pharmacokinetic (PK) and bioequivalence (BE) / formulation work to support generic product lifecycle management
• Cardiovascular and safety signal monitoring that typically relies on large, pragmatic cohorts rather than brand-new phase-3 registrational programs

At global scale, the most clinically consequential datasets for sulfonylureas have historically come from large randomized outcome trials and meta-analyses rather than ongoing brand-new “first-of-kind” trials for glimepiride itself. Today, most remaining “trial updates” for glimepiride are incremental: BE programs and comparative trials that support labeling consistency or local market approvals.

Practical implication for R&D and investment: new value creation from glimepiride is most likely to come from fixed-dose combinations, optimized dosing regimens, or safety-driven positioning, not from standalone, patent-led innovation.

---

What is the competitive landscape for glimepiride in T2DM?

Which drug classes take share from sulfonylureas?

Market share pressure typically comes from:

• SGLT2 inhibitors (CV benefit framing in many guidelines)
• GLP-1 receptor agonists (weight loss and glycemic control)
• DPP-4 inhibitors (tolerability)
• Thiazolidinediones in some markets (where still used)

Sulfonylureas retain use because they are:

• Low cost
• Oral
• Clinician familiar
• Effective for A1c reduction, but with known risks such as hypoglycemia and weight gain relative to some newer agents

How guideline dynamics affect utilization

Utilization of glimepiride is sensitive to:

• Payer cost controls that favor low-cost generics
• Cardio-renal phenotype pathways that push SGLT2/GLP-1 earlier for eligible patients
• Hypoglycemia risk management (dose titration, patient selection, discontinuation or switch in frail populations)

---

What does market analysis say about glimepiride demand drivers?

Demand drivers

Glimepiride consumption tracks with:

• T2DM prevalence growth
• High generic penetration in core markets
• Ongoing need for effective oral intensification after metformin
• Budget-constrained prescribing in many geographies

Demand drag

Key headwinds:

• Shift toward newer agents in guideline-directed practice
• Formulary restrictions that prefer SGLT2/GLP-1 for patients with CV risk, CKD, or obesity
• Safety burden tied to hypoglycemia, especially in elderly and renal impairment subgroups
• Patent and brand churn does not apply materially to glimepiride (generic advantage is dominant), so marginal innovation is limited

---

Market sizing and projection framework

A precise global projection for glimepiride requires region-by-region branded and generic volume data and payer mix. In the absence of a single consolidated, authoritative number in the provided source set, the correct approach for business decisions is to project using T2DM patient growth and sulfonylurea share assumptions.

This forecast is therefore built as a scenario model that maps:

• T2DM incidence and prevalence growth
• Oral glucose-lowering versus incretin uptake
• Sulfonylurea competitive share
• Price effects from generic erosion

Scenario model: 2025 to 2030

Assume glimepiride volumes track overall sulfonylurea volumes, with price declining or stagnating due to generic competition. The core uncertainty is share shift out of sulfonylureas toward SGLT2/GLP-1.

Table 1. Projection logic (directional, business-useful)	Driver	2025 baseline effect	2026-2030 effect	Net impact on glimepiride
T2DM pool growth	Up	Up	Supports volume
Oral-to-injectable migration	Flat/slight down	Down	Reduces volume
Incretin adoption in high-risk phenotypes	Up	Up	Accelerates share loss
Generic price erosion	Ongoing	Ongoing	Reduces value, may mask volume stability
Hypoglycemia-related preference shifts	Stable	Slightly down	Slight additional share loss

Interpretation: Across scenarios, glimepiride is expected to show stabilizing or slowly declining global unit demand and declining or flat revenue value due to persistent generic pricing pressure. The “best case” preserves volume via payer cost preference; the “base case” shows gradual share loss; the “worst case” accelerates shift toward SGLT2/GLP-1.

---

What is the likely revenue trajectory?

Value (revenue) is structurally capped

For legacy off-patent drugs, market value is constrained by:

• Generic price compression
• Multiple manufacturers
• Tender-driven pricing and reimbursement controls

Volume is supported by low-cost access

Even with share losses, glimepiride remains a default option in many settings:

• When cost and formulary rules restrict newer agents
• When patients cannot tolerate or do not have access to incretins or SGLT2 inhibitors
• When insulin initiation is delayed

---

Where do glimepiride trials still matter for commercialization?

Clinical trials influence the market mainly through:

• Safety and tolerability evidence that supports guideline continuation
• Comparative efficacy results in subpopulations (renal impairment, elderly, combination therapy)
• Pragmatic effectiveness that helps payers justify continued use

If a new glimepiride dossier is being considered commercially, the strongest routes are typically:

• Combination development (fixed-dose or co-pack strategies)
• Formulation improvements that reduce dosing burden or mitigate adverse events
• Real-world studies that validate persistence and adherence

---

Key takeaways

1. Glimepiride is a mature sulfonylurea with market dynamics dominated by generic pricing and guideline-driven share migration toward SGLT2 inhibitors and GLP-1 receptor agonists.
2. Clinical trial relevance is incremental: most activity is comparative, safety-focused, or BE/formulation driven rather than new registrational breakthroughs.
3. Projection direction is stable-to-declining units and softer value through 2030 as oral-incretin migration accelerates while generic erosion continues.
4. The highest leverage path for any future commercial strategy is combination or formulation and payer-friendly evidence tied to safety management, not standalone innovation.

---

FAQs

1) Is glimepiride still used in current T2DM treatment algorithms?

Yes. It remains a common oral option in cost-sensitive settings and as an intensification agent where incretin or SGLT2 access is limited.

2) What most limits glimepiride growth?

Hypoglycemia and weight gain risk compared with incretin-based and SGLT2-based pathways, plus payer and guideline shifts toward those classes.

3) Are there new patent-driven glimepiride therapies coming?

As a legacy generic, market impact from “brand-new” glimepiride patent assets is typically limited. Commercial changes usually come from reformulations, combinations, and regional generics.

4) How should investors interpret a flat prescription trend for glimepiride?

Flat prescriptions can coexist with declining revenue because generic price erosion reduces value even if units hold.

5) What clinical evidence moves prescribing decisions most for sulfonylureas?

Safety signals around hypoglycemia risk, comparative A1c outcomes in combination regimens, and real-world persistence/adherence in representative patient cohorts.

---

References (APA)

[1] International Diabetes Federation. (2021). IDF Diabetes Atlas (10th ed.). https://diabetesatlas.org
[2] NCBI. (2024). Glimepiride (PubChem compound summary). https://pubchem.ncbi.nlm.nih.gov
[3] U.S. Food and Drug Administration. (n.d.). FDA-approved labeling information (glimepiride products and class information). https://www.accessdata.fda.gov